Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris

British Journal of Dermatology

Volumn 172, Issue 1, 2015, Pages 244-252

  Gniadecki, R ^a   Bang, B ^a   Bryld, L E ^b   Iversen, L ^c   Lasthein, S ^d   Skov, L ^b  

^a BISPEBJERG HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; USTEKINUMAB; BIOLOGICAL FACTOR; DERMATOLOGICAL AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; DENMARK; DERMATOLOGY LIFE QUALITY INDEX; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; LUPUS LIKE SYNDROME; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSORIASIS VULGARIS; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; ADULT; COMPARATIVE STUDY; DRUG SUBSTITUTION; PROSPECTIVE STUDY; PSORIASIS;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL FACTORS; DERMATOLOGIC AGENTS; DRUG SUBSTITUTION; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; PROSPECTIVE STUDIES; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME;

EID: 84920755313     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13343     Document Type: Article

References (22)

1. Rustin MHA,. Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data. Br J Dermatol 2012; 167 (Suppl.): 3-11.
2. Gordon K, Papp K, Poulin Y, et al,. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol 2012; 66: 241-51.
3. Papp KA, Poulin Y, Bissonnette R, et al,. Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. J Am Acad Dermatol 2010; 66: e33-45.
4. Kimball AB, Gordon KB, Fakharzadeh S, et al,. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol 2012; 166: 861-72.
5. Gniadecki R, Kragballe K, Dam TN, Skov L,. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol 2011; 164: 1091-6.
6. Esposito M, Gisondi P, Cassano N, et al,. Survival rate of anti-TNF alpha treatments for psoriasis in routine dermatological practice: a multicenter observational study. Br J Dermatol 2013; 169: 666-72.
7. Lõpez-Ferrer A, Vilarrasa E, Gich IJ, Puig L,. Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre. Br J Dermatol 2013; 169: 1141-7.
8. Van den Reek JMPA, van Lümig PPM, Driessen RJB, et al,. Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis. Br J Dermatol 2014; 170: 415-24.
9. Mattei PL, Corey KC, Kimball AB,. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol 2014; 28: 333-7.
10. Mehren CR, Clemmensen A, Dall AB-H, et al,. Essential factors influencing health-related-quality of life in psoriasis. J Drugs Dermatol 2014; 13: 246-50.
11. Menting SP, Sitaram AS, Bonnerjee-van der Stok HM, et al,. Drug survival not significantly different between biologics in patients with psoriasis vulgaris: a single-centre database analysis. Br J Dermatol 2014; 171: 875-83.
12. van den Reek JM, Zweegers J, Kievit W, et al,. 'Happy' drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care-results from the BioCAPTURE network. Br J Dermatol 2014; 171: 1189-96.
13. Reich K, Burden AD, Eaton JN, Hawkins NS,. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. Br J Dermatol 2012; 166: 179-88.
14. Papoutsaki M, Talamonti M, Giunta A, et al,. The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab. Dermatology 2010; 221 (Suppl. 1): 43-7.
15. Mehren CR, Gniadecki R,. Dose-creep of infliximab during psoriasis treatment: an observational study. Acta Derm Venereol 2012; 92: 355-7.
16. Kimball AB, Papp KA, Wasfi Y, et al,. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol 2013; 27: 1535-45.
17. Clemmensen A, Spon M, Skov L, et al,. Responses to ustekinumab in the anti-TNF agent-naïve vs. anti-TNF agent-exposed patients with psoriasis vulgaris. J Eur Acad Dermatol Venereol 2011; 25: 1037-40.
18. Reich K, Puig L, Paul C, et al,. One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis. Br J Dermatol 2014; 170: 435-44.
19. Hetland ML, Christensen IJ, Tarp U, et al,. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010; 62: 22-32.
20. Glintborg B, Ostergaard M, Krogh NS, et al,. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO registry. Arthritis Rheum 2013; 65: 1213-23.
21. Wolbink GJ, Aarden LA, Dijkmans BAC,. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol 2009; 21: 211-15.
22. Van Schouwenburg PA, van de Stadt LA, de Jong RN, et al,. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann Rheum Dis 2013; 72: 104-9.